

FOR IMMEDIATE RELEASE

Company Name Kyowa Kirin Co., Ltd.
Representative Masashi Miyamoto, President and CEO
(Code No. 4151, Prime Market of TSE)
Inquiries Satoko Yoshida, Director,
Corporate Communications Department
Media Contact: +81-3-5205-7205
Investor Contact: +81-3-5205-7206

Notice regarding Completion of Share Acquisition of Orchard Therapeutics plc (overview of the acquisition)

Tokyo, January 25, 2024 - As announced in the “Notice regarding Agreement to acquire Shares of UK biopharmaceutical company Orchard Therapeutics plc” on October 5, 2023, and “Notice regarding Completion of Share Acquisition of Orchard Therapeutics plc” on January 24, 2024, Kyowa Kirin Co., Ltd. (President and CEO: Masashi Miyamoto, “Kyowa Kirin”) completed to acquire 100% of the outstanding shares of Orchard Therapeutics plc (CEO: Bobby Gaspar).

The overview of the acquisition is being announced as follows.

1. Overview of Orchard

(1) Name	Orchard Therapeutics plc
(2) Location	245 Hammersmith Road, 3rd Floor London W6 8PW United Kingdom
(3) Job title and name of representative	Chief Executive Officer Bobby Gaspar
(4) Description of business	Development and commercialization of hematopoietic stem cell gene therapy
(5) Share capital	\$29,463 thousand (as of September 30, 2023)
(6) Year of establishment	2015

2. Number of shares acquired, acquisition costs, and shareholding before and after acquisition

(1) Number of shares held before the change*	0 shares (Number of voting rights: 0 units) (Ratio of voting rights held: 0%)
(2) Number of shares acquired	22,817,354 shares (Number of voting rights: 18,246,822 units)
(3) Acquisition costs* **	\$16.00 per ADS, \$387.6million (Approximately JPY 57.4 billion)
(4) Number of shares held after the change	22, 817,354 shares (Ratio of voting rights held: 100%)

*Acquisition costs include all outstanding common shares, ADSs, options, Restricted Stock Units,

and other instruments. Additional \$1.00 contingent value rights (CVR) will be paid for a total of \$17.00 per ADS, or approximately \$477.8 million (approximately JPY 70.7 billion) if OTL-200 is approved by the U.S. Food and Drug Administration for the commercial marketing and sale in the U.S.

**Calculated at the rate of USD = JPY 148

3. Outlook

The administrative and financial impact of this acquisition on Kyowa Kirin will be disclosed in conjunction with the 2023 earnings announcement on February 7.

End